Click here to register.

Join us in our upcoming webinar titled 'FDA/EMA Approved Drugs Entering China Market without NMPA’s Approval' on Wednesday, Dec 16th at 9 AM EST/ 3 PM CET/ 9 PM Beijing Time!

This time we invite Ms. Helen Hsu, Partner (Medical Officer) at MSQ Ventures, to share the special regulatory pathway for FDA/EMA approved drugs to enter the China market without NMPA’s (China National Medical Products Administration’s) approval in Hainan and Shenzhen.

Ms. Echo Hindle-Yang, President & CEO, will be moderating this discussion.

About Helen Hsu:

Helen Hsu, physician (M.D.) with 20+ years of research program development, medical affairs and advisory experience in the Pharmaceutical Industry, Academia and Clinical Setting. She has more than 10 years of IRB experience in regulatory compliance and GCP guidelines. She previously worked at Evergrande Health, Boehringer Ingelheim, Novartis, and GSK, and has translational research experience from East Maine Medical Center, NYU Medical School affiliated hospital and Albert Einstein College of Medicine.

Helen received M.S. in Molecular Biology and Clinical Laboratory Science from Michigan State University, and M.D. from China Southeastern University Medical College.